MYOV stock: buy or sell?

MYOV stock price: $12.78 2.08% At close on May 21st, 2019

Updated on:
May 21st, 2019


Myovant Sciences shares rose 2.08% to $12.78 today. On Thursday MYOV plunged a bloodcurdling -5.46%. On Wednesday MYOV climbed an astounding 5.03%.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases.

Should I buy MYOV stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Myovant Sciences stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Myovant Sciences stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we detected 2 ratings published for MYOV stock in the last month.

Is MYOV a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-2-13BarclaysEqual WeightOverweight
2019-2-11JMP Securitiesn/aBuy

MYOV stock analysis

Daily outlook

Shares of Myovant Sciences closed today at $12.78 and rose a shining 2.08%.

Shares of Myovant Sciences rose a shining 2.08% and closed at $12.78. Since April 11th when MYOV stock price broke down the SMA200d line, it slid $-9.10 per share (-41.59%). MYOV is soaring again after a 15.87% correction from its last top on Wednesday at $13.93. Since SMA50d and SMA100d crossed up on March, MYOV price slid a -40.92%.

MYOV stock chart (daily)

Weekly outlook

After sliding a chilling -42.23% in a week last week, Myovant Sciences closed this week at $12.78 and soared a nice 2.40%.

Since price and 40-weeks moving average lines crossed down early April, MYOV fell $-11.66 per share (-47.71%). Stocks under the 200d moving average line are usually not recommended for average traders. Far behind is the all-time high Myovant Sciences hit late September 2018 and since then the price is -53.44% below that top.

MYOV stock chart (weekly)

MYOV stock price history

MYOV IPO was on October 27th, 2016 at $15.00 per share1. Since then, MYOV stock lost a -14.80%, with a yearly average of -7.40%.

1: Adjusted price after possible price splits or reverse-splits.

MYOV stock historical price chart

MYOV stock reached all-time highs on September with a price of $27.45.

MYOV stock price target is $25.00

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 2 price forecasts for Myovant Sciences stock:
MYOV stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-2-11JMP SecuritiesReiteratesn/a$25.00-
(in average)$22.00$25.0014.0%
The price prediction for Myovant Sciences stock is $25.00, moving in a range between $25.00 and $25.00. In average, analysts' outlook on MYOV price target is positive, improving the target by a 14.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Myovant Sciences reported its latest financial data, posting a slightly fine growth for the Earnings per Share (EPS) ratio. Analyst expected $-0.99 per share, but Myovant Sciences posted $-1.04.
MYOV earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In , Myovant Sciences annual turnover to M USD from marked in . , its profit margin (compared to sales) to , that is million.

MYOV annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-70.63 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Myovant Sciences sales marked a tight move and remained steady a nan%. Looking back to recent quarterly results, Myovant Sciences posted 7 positive quarters in a row.
MYOV quarterly Sales and Income evolution

Myovant Sciences ownership

When you are planning to invest in a stock, it's always worth to overview its ownership structure.

Myovant Sciences shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 67.07% of all shares.

In case of Myovant Sciences stock, 31.04% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for MYOV stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Myovant Sciences:

Market cap$905.0 M$366.8 M$180.5 M
Total shares70.8 M120.7 M49.2 M
Float shares19.6 M109.4 M49.1 M
  - Institutional holdings (%)31.0%95.2%72.8%
  - Insider holdings (%)67.1%2.5%0.2%
Shares in short selling0.0%0.0%0.0%

MYOV summary

Tuesday, May 21st, 2019
Day range$12.42 - $12.97
Previous close$12.52
Session gain2.08%
Average true range$1.10
50d mov avg$20.00
100d mov avg$19.71
200d mov avg$20.48
Daily patternlb01a
Weekly pattern

Myovant Sciences performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Myovant Sciences against PDL BioPharma and Pieris Pharmaceuticals in the following table:
MYOVMyovant Sciences-40.31%-33.92%-43.35%
PDLIPDL BioPharma-15.79%1.33%8.19%
PIRSPieris Pharmaceut...19.16%6.69%-41.19%

Myovant Sciences competitors

Creating a list of competitors for Myovant Sciences it's difficult. We selected 2 public companies that are related to and can be considered as competitors of Myovant Sciences: